BRIEF—Hemogenyx and J&J collaborate on lupus research

A subsidiary of London-based Hemogenyx Pharmaceuticals has entered into a collaboration with Johnson & Johnson, to develop a model of systemic lupus erythematosus (SLE), the most common form of lupus.

Immugenyx, which has research facilities in New York, USA, will use its advanced hematopoietic chimeras (AHC) as an in vivo platform for disease modelling and drug development.

According to the terms of the agreement, Hemogenyx shall own the humanized mouse model, while J&J will gain a non-exclusive, fully-paid-up global license to use it. Financial terms were not disclosed.